Akero Therapeutics Inc.

NASDAQ: AKRO · Real-Time Price · USD
49.42
-0.67 (-1.34%)
At close: Aug 15, 2025, 3:59 PM
48.69
-1.48%
After-hours: Aug 15, 2025, 07:10 PM EDT

Akero Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 4K n/a n/a n/a 284K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a n/a 2K 1K 1K 1K 2K 5K 69K 68K 65K 66K 65K 64K 63K 60K 60K 61K
Gross Profit
n/a n/a 2K -1K -1K -1K -2K -5K -69K -68K -65K -66K -65K -64K -63K -60K -60K -61K
Operating Income
-80.87M -80.88M -78.03M -81.7M -65.74M -59.95M -61.87M -46.62M -35.63M -28.75M -25.42M -36.09M -27.59M -26.05M -32.44M -24.35M -28.97M -15.13M
Interest Income
11.54M 11.31M 9.2M 10.24M 10.98M 7.6M 7.58M 7.84M 5.4M 3.38M n/a n/a 244K 22K n/a n/a n/a 38K
Pretax Income
-70.5M -70.72M -70.02M -72.7M -55.99M -53.34M -55.19M -39.66M -31.08M -25.83M -23.06M -35.54M -27.4M -26.03M -32.42M -24.33M -28.93M -15.09M
Net Income
-70.5M -70.72M -70.02M -72.7M -55.99M -53.34M -55.19M -39.66M -31.08M -23.37M -20.48M -34.99M -27.4M -26.01M -32.42M -24.33M -28.93M -15.09M
Selling & General & Admin
11.62M 11.31M 8.73M 9.47M 10.42M 9.3M 8.48M 7.98M 7.64M 6.97M 7.1M 11M 6.23M 5.54M 4.73M 4.88M 4.99M 4.53M
Research & Development
69.25M 69.57M 69.29M 72.23M 55.32M 50.65M 53.39M 38.63M 27.98M 21.79M 18.32M 25.09M 21.36M 20.51M 27.71M 19.47M 23.98M 10.6M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 244K n/a 15K 23K 33K 38K
Operating Expenses
80.87M 80.88M 78.03M 81.7M 65.74M 59.95M 61.87M 46.62M 35.63M 28.75M 25.42M 36.09M 27.59M 26.05M 32.44M 24.35M 28.97M 15.13M
Interest Expense
1.17M -1.15M 1.2M 1.25M 1.23M 991K 897K 888K 857K 457K 362K 324K 53K n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a -1K -1K -2K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
80.87M 80.88M 78.03M 81.7M 65.74M 59.95M 61.87M 46.62M 35.63M 28.75M 25.42M 36.09M 27.59M 26.05M 32.44M 24.35M 28.97M 15.13M
Income Tax Expense
n/a n/a n/a n/a n/a -42.28K n/a n/a n/a -2.46M -2.57M -549K n/a -22K -11K -51K -50K -50K
Shares Outstanding (Basic)
81.72M 78.66M 70.57M 69.44M 69.16M 59.31M 55.72M 55.61M 51.87M 46.94M 46.76M 38.66M 35.38M 35.01M 34.89M 34.86M 34.81M 34.74M
Shares Outstanding (Diluted)
81.72M 78.66M 70.57M 69.44M 69.16M 59.31M 55.72M 55.61M 51.87M 46.94M 46.76M 38.66M 35.38M 35.01M 34.89M 34.86M 34.81M 34.74M
EPS (Basic)
-0.86 -0.9 -0.99 -1.05 -0.81 -0.9 -0.99 -0.71 -0.6 -0.5 -0.44 -0.91 -0.77 -0.74 -0.93 -0.7 -0.83 -0.43
EPS (Diluted)
-0.86 -0.9 -0.99 -1.05 -0.81 -0.9 -0.99 -0.71 -0.6 -0.5 -0.44 -0.91 -0.77 -0.74 -0.93 -0.7 -0.83 -0.43
EBITDA
-69.33M -69.57M -68.81M -71.46M -54.76M -52.35M -54.29M -38.77M -30.16M -25.31M -22.63M -35.15M -27.29M -25.96M -32.43M -24.27M -28.87M -15.12M
EBIT
-69.33M -69.57M -68.82M -71.46M -54.76M -52.35M -54.29M -38.77M -30.23M -25.37M -22.7M -35.22M -27.35M -26.03M -32.44M -24.33M -28.93M -15.13M
Depreciation & Amortization
n/a 4.5K 15K 1K 1K 1K 2K 5K 69K 68K 65K 66K 65K 64K 63K 60K 60K 61K